CSAHi study‐2: Validation of multi‐electrode array systems (MEA60/2100) for prediction of drug‐induced proarrhythmia using human iPS cell‐derived cardiomyocytes: Assessment of reference compounds and comparison with non‐clinical studies and clinical information

ABSTRACT With the aim of reconsidering ICH S7B and E14 guidelines, a new in vitro assay system has been subjected to worldwide validation to establish a better prediction platform for potential drug‐induced QT prolongation and the consequent TdP in clinical practice. In Japan, CSAHi HEART team has been working on hiPS‐CMs in the MEA (hiPS‐CMs/MEA) under a standardized protocol and found no inter‐facility or lot‐to‐lot variability for proarrhythmic risk assessment of 7 reference compounds. In this study, we evaluated the responses of hiPS‐CMs/MEA to another 31 reference compounds associated with cardiac toxicities, and gene expression to further clarify the electrophysiological characteristics over the course of culture period. The hiPS‐CMs/MEA assay accurately predicted reference compounds potential for arrhythmogenesis, and yielded results that showed better correlation with target concentrations of QTc prolongation or TdP in clinical setting than other current in vitro and in vivo assays. Gene expression analyses revealed consistent profiles in all samples within and among the testing facilities. This report would provide CiPA with informative guidance on the use of the hiPS‐CMs/MEA assay, and promote the establishment of a new paradigm, beyond conventional in vitro and in vivo assays for cardiac safety assessment of new drugs. HIGHLIGHTShiPS‐CMs/MEA accurately predicted reference compounds potential for arrhythmia.Gene expressions showed high correlation among the facility and inter‐facility.This system is suitable as a new non‐clinical testing of drugs cardiac liabilities.